Project Summary Ischemic heart disease is the leading cause of death worldwide. To approach this major public health epidemic, two prevailing areas of study have emerged: 1) Cell therapy aimed at delivering culture-expanded pluripotent cells by coronary artery infusion after an ischemic event, and 2) Endogenous cardiac progenitor cells (CPCs) and their potential role for in vivo renewal and regeneration of the myocardium. Initially these two topics seemed inextricably linked, but it is now becoming clear that while delivery of CPCs for therapy may provide some mechanistically-unexplained benefit, the retention of these cells into the myocardium is marginal and de novo cardiomyocyte differentiation is even less common. A population of putative CPCs, marked by the tyrosine kinase receptor, c-Kit, have been a common focus in both areas of study. Our lab recently published a genetic lineage tracing model demonstrating the cardiac contribution of the Kit lineage in the heart which showed conclusively that Kit-derived cells rarely become cardiomyocytes, but have a high propensity for the formation of vascular endothelium. Furthermore, this study demonstrated that approximately 80% of Kit lineage-traced cardiomyocytes were actually derived from fusion events and the sought-after de novo cardiomyocyte was even more rare than originally believed. To validate this study, we aimed to eliminate the ability of Kit-derived cells to make any de novo cardiomyocytes by knocking out essential cardiomyogenic transcription factor, Gata4, theoretically allowing only for lineage-traced cardiomyocytes derived from fusion. Interestingly, the appearance of Kit lineage-traced cardiomyocytes due to fusion increased dramatically with the loss of Gata4 in the Kit lineage, and, furthermore, we observed a dramatic increase of both Kit-lineage cells in the heart and total cardiac vascular endothelium. We now hypothesize that what is uniting these findings is a novel role for Gata4 in the adult vascular endothelium, and what initially appeared to be an interesting driver of innate fusigenic character with cardiomyocytes is most likely an incidental readout due to increased vascular permeability and neoangiogenesis. While many GATA transcription factors have had previously reported roles in vascular development, including Gata4, few studies have focused on adult vascular homeostasis. Better understanding of this Gata4-mediated transcriptional control of vascular expansion could provide meaningful insight into mechanisms of cardiac renewal and repair. To address this novel role of Gata4 in the cardiac vascular endothelium, we will pursue the following aims: (1) Determine whether endothelial-specific loss of Gata4 leads to increased vascular permeability and enhanced angiogenesis; (2) Assess changes in cardiac recovery after deletion of Gata4 in the adult cardiac endothelium.

Project Narrative: Relevance to Public Health Myocardial angiogenesis remains an attractive area for therapeutic treatment of ischemic heart disease, especially with the continued shortcomings of studies seeking cardiomyocyte replacement following myocardial infarction. The experiments outlined in this application seek to discover the mechanism by which Gata4 loss in the vascular endothelium leads to increased angiogenesis, and determine if this increased expansion provides therapeutic benefit either prophylactically or immediately reactive to ischemia. Clinical implications include the identification of new therapeutic targets to aid in prevention or treatment of ischemic heart disease.